AT502722B8 - Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren - Google Patents

Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren Download PDF

Info

Publication number
AT502722B8
AT502722B8 AT0179005A AT17902005A AT502722B8 AT 502722 B8 AT502722 B8 AT 502722B8 AT 0179005 A AT0179005 A AT 0179005A AT 17902005 A AT17902005 A AT 17902005A AT 502722 B8 AT502722 B8 AT 502722B8
Authority
AT
Austria
Prior art keywords
interferone
isg
ifi
nuclear receptors
induced gene
Prior art date
Application number
AT0179005A
Other languages
English (en)
Other versions
AT502722B1 (de
AT502722A1 (de
Original Assignee
Bmt Medizinische Forschung Und
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bmt Medizinische Forschung Und filed Critical Bmt Medizinische Forschung Und
Priority to AT0179005A priority Critical patent/AT502722B8/de
Priority to PCT/AT2006/000448 priority patent/WO2007051218A2/de
Priority to US12/092,189 priority patent/US20080313751A1/en
Priority to EP06804375A priority patent/EP1945805A2/de
Publication of AT502722A1 publication Critical patent/AT502722A1/de
Publication of AT502722B1 publication Critical patent/AT502722B1/de
Application granted granted Critical
Publication of AT502722B8 publication Critical patent/AT502722B8/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/323Arteriosclerosis, Stenosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT0179005A 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren AT502722B8 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren
PCT/AT2006/000448 WO2007051218A2 (de) 2005-10-31 2006-10-31 Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken
US12/092,189 US20080313751A1 (en) 2005-10-31 2006-10-31 Method by Using Human or Mice-Isg12 to Develop and Prepare Drugs and Single Nucleotide Polymorphism in the Isg12 Gene for Diagnostic Use
EP06804375A EP1945805A2 (de) 2005-10-31 2006-10-31 Verfahren unter verwendung von humanem oder mäuse-isg12 zur entwicklung und herstellung von medikamenten sowie von single-nucleotide-polymorphismus im isg12-gen zu diagnosezwecken

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren

Publications (3)

Publication Number Publication Date
AT502722A1 AT502722A1 (de) 2007-05-15
AT502722B1 AT502722B1 (de) 2009-07-15
AT502722B8 true AT502722B8 (de) 2009-08-15

Family

ID=38006218

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0179005A AT502722B8 (de) 2005-10-31 2005-10-31 Verwendung des interferon induzierten gens 12 (isg 12, ifi 27) zur modulation transkriptioneller aktivitäten von nuklearen rezeptoren

Country Status (4)

Country Link
US (1) US20080313751A1 (de)
EP (1) EP1945805A2 (de)
AT (1) AT502722B8 (de)
WO (1) WO2007051218A2 (de)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141455A1 (en) * 2002-01-08 2006-06-29 Rhonda Hansen Gene products differentially expressed in cancerous breast cells and their methods of use
WO2005000087A2 (en) * 2003-06-03 2005-01-06 Chiron Corporation Gene products differentially expressed in cancerous colon cells and their methods of use ii
US20020137081A1 (en) * 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
US6681543B2 (en) * 2001-03-28 2004-01-27 Toyoda Gosei Co., Ltd. Vehicle molding and method for attaching the vehicle molding
WO2004011618A2 (en) * 2002-07-29 2004-02-05 Hmgene, Inc. Methods of identifying adipocyte specific genes, the genes identified, and their uses
JP2006514823A (ja) * 2002-08-20 2006-05-18 ミレニアム ファーマスーティカルズ インク 子宮頸癌の同定、評価、予防および治療を行うための組成物、キットおよび方法
US20050009067A1 (en) * 2003-05-19 2005-01-13 Craig Logsdon Expression profile of pancreatic cancer
JP2005204549A (ja) * 2004-01-21 2005-08-04 Hubit Genomix Inc C型肝炎ウイルス感染者の経過に関する遺伝子およびその利用

Also Published As

Publication number Publication date
WO2007051218A3 (de) 2007-09-20
AT502722B1 (de) 2009-07-15
EP1945805A2 (de) 2008-07-23
WO2007051218A2 (de) 2007-05-10
AT502722A1 (de) 2007-05-15
US20080313751A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
MA28985B1 (fr) Analogues de loxapine et methodes d'utilisation
DE502005006470D1 (de) Verwendung von sulfonylharnstoffen
EA200901653A1 (ru) ОПОСРЕДУЕМОЕ PHKi ИНГИБИРОВАНИЕ ЭКСПРЕССИИ АЛЬФА-EnaC
TW200716624A (en) Compounds for modulating TRPV3 function
EP1395113A4 (de) Verwendung von follistatin zur erhöhung der muskelmasse
WO2006049734A3 (en) Quetiapine analogs and methods of use thereof
EP2367974A4 (de) Modifizierung von biomasse zur effizienten verwertung von brennstoffen
BR112013005116A2 (pt) moduladores e métodos de uso
EP3846563C0 (de) Steuerkanalsignalisierung unter verwendung von codepunkten zur anzeige des zeitplanungsmodus
EP2203058A4 (de) Verfahren und verbindungen zur modulation der cannabinoidaktivität
EP2376085A4 (de) Verbindungen und anwendungsverfahren
DE602004010791D1 (de) 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren
CR10213A (es) Moduladores de la proteína quinasa aurora
DK2173730T3 (da) Hidtil ukendte forbindelser 951: biphenyloxypropansyre som crth2-modulator og mellemprodukter
BR112013014119A8 (pt) Novos moduladores e métodos de uso
DE602005002836D1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
EP3989925A4 (de) Zusammensetzung zum färben von keratinfasern und ihre verwendung
DE602007008222D1 (de) Diazepanderivate als modulatoren von chemokinrezeptoren
EP2306823A4 (de) Formulierungen von 5-fluorcytosin und ihre verwendungen
BRPI0910548A2 (pt) método e aparelho para ligar esquema de modulação codificada à quantidade de recursos.
ATE510556T1 (de) Verwendung von erythropoietin
EP1814394A4 (de) Verwendung von antioxidationsmitteln zur genmodulation
DE60306716D1 (de) Drucker mit Mitteln zur Vermeidung von Überhitzung
DE60322898D1 (de) Verwendung von isoflavonen zur förderung des schlankheitseffekts
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung

Legal Events

Date Code Title Description
EIH Change in the person of patent owner
MM01 Lapse because of not paying annual fees

Effective date: 20131031